Home Newsfeeds Wolfe Research Initiates Coverage On SunPower with Peer Perform Rating

Wolfe Research Initiates Coverage On SunPower with Peer Perform Rating

Wolfe Research analyst Steve Fleishman initiates coverage on SunPower (NASDAQ:SPWR) with a Peer Perform rating.

byBenzinga Newsdesk

December 13, 2022

1 minute read

Wolfe Research analyst Steve Fleishman initiates coverage on SunPower (NASDAQ:SPWR) with a Peer Perform rating.

Analyst Ratings

Where Wolverine World Wide Stands With Analysts

By Benzinga Insights

December 8, 11:06 AM

Wolverine World Wide (NYSE:WWW) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…

WWW

Investor Fear Eases; US Stocks Settle Lower

By Lisa Levin

March 29, 3:07 AM

The CNN Money Fear and Greed index showed some easing in the fear level among U.S. investors. US stocks dropped on Tuesday, amid an increase in bond yields, which exerted pressure on tech stocks in particular.

CTAS

Reported Late Wednesday, Oramed Pharmaceuticals Announces Top-line Results From Phase 3 Trial Of ORMD-0801 For The Treatment Of Type 2 Diabetes

By Benzinga Newsdesk

January 12, 1:42 AM

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized,

ORMP

Sensei Biotherapeutics To Present Topline Clinical Data From The SNS-101 Phase I Dose Escalation Study At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

April 24, 4:52 PM

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical

SNSE

Wolfe Research Initiates Coverage On SunPower with Peer Perform Rating

Related Posts

Where Wolverine World Wide Stands With Analysts

Investor Fear Eases; US Stocks Settle Lower

Reported Late Wednesday, Oramed Pharmaceuticals Announces Top-line Results From Phase 3 Trial Of ORMD-0801 For The Treatment Of Type 2 Diabetes

Sensei Biotherapeutics To Present Topline Clinical Data From The SNS-101 Phase I Dose Escalation Study At The 2024 ASCO Annual Meeting